Table 4.
Relationship between improvement in HOMA-IR and metabolic parameters/endocrinological findings examined with the Fisher exact test.
| Regression analysis | Improvement in HOMA-IR | ||
|---|---|---|---|
| β (SE) | 95% CI | P | |
| Age | −0.188 (0.378) | −1.044 to 0.668 | .631 |
| Sex | −3.290 (17.832) | −43.629 to 37.049 | .858 |
| Improvement in BMI | −2.225 (3.581) | −10.325 to 5.874 | .550 |
| Improvement in AST | 0.157 (0.560) | −1.108 to 1.423 | .785 |
| Improvement in ALT | 0.145 (0.303) | −0.539 to 0.829 | .643 |
| Improvement in γ-GTP | 0.332 (0.508) | −0.816 to 1.480 | .529 |
| Presence of deficiency of ACTH | 7.076 (13.636) | −23.772 to 37.923 | .616 |
| Presence of deficiency of TSH | 7.076 (13.636) | −23.772 to 37.923 | .616 |
| Presence of deficiency of LH | 0.881 (13.836) | −30.417 to 32.180 | .951 |
| Presence of deficiency of FSH | 0.881 (13.836) | −30.417 to 32.180 | .951 |
| Presence of central diabetes insipidus | 23.573 (22.645) | −27.653 to 74.799 | .325 |
| Replacement therapy of hydrocortisone | 7.076 (13.636) | −23.772 to 37.923 | .616 |
| Replacement therapy of levothyroxine | 19.222 (12.811) | −9.759 to 48.204 | .168 |
| Replacement therapy of desmopressin | 23.573 (22.645) | −27.653 to 74.799 | .325 |
| Periods of daily GH replacement therapy | 4.463 (1.949) | 0.055 to 8.871 | .048* |
β = regression coefficient; γ-GTP = γ-glutamyl transferase; ACTH = adrenocorticotropic hormone; ALT = alanine aminotransferase; AST = aspartate transaminase; BMI = body mass index; CI = confidence interval; FSH = follicle-stimulating hormone; GH = growth hormone; HOMA-IR = homeostasis model assessment of insulin resistance; LH = luteinizing hormone; SE = standard error; TSH = thyroid-stimulating hormone.
P < .05 (*) was considered significant.